Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats

Neuroscience

Volumn 190, Issue , 2011, Pages 339-345

  Ye, X ^a,b   Chopp, M ^b,c   Liu, X ^a   Zacharek, A ^b   Cui, X ^b   Yan, T ^b   Roberts, C ^b   Chen, J ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b HENRY FORD HOSPITAL   (United States)

^c OAKLAND UNIVERSITY   (United States)

Author keywords

HMGB1; MMP 9; Niaspan; RAGE; Stroke; Type 1 diabetes rats

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; NICOTINIC ACID; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEDIATOR RELEASE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION; SLOW DRUG RELEASE; STREPTOZOCIN DIABETES; STROKE; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; BRAIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; HMGB PROTEINS; MALE; NIACIN; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; STROKE;

EID: 80051589315     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.06.004     Document Type: Article

References (42)

1. Like A.A., Rossini A.A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976, 193:415-417.
2. Barile G.R., Schmidt A.M. RAGE and its ligands in retinal disease. Curr Mol Med 2007, 7:758-765.
3. Bianchi R., Adami C., Giambanco I., Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. J Leukoc Biol 2007, 81:108-118.
4. Bianchi R., Giambanco I., Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging 2010, 31:665-677.
5. Calza L., Giardino L., Giuliani A., Aloe L., Levi-Montalcini R. Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc Natl Acad Sci U S A 2001, 98:4160-4165.
6. Chen J., Cui X., Zacharek A., Cui Y., Roberts C., Chopp M. White matter damage and the effect of matrix metalloproteinases in type 2 diabetic mice after stroke. Stroke 2011, 42:445-452.
7. Chen J., Cui X., Zacharek A., Jiang H., Roberts C., Zhang C., Lu M., Kapke A., Feldkamp C.S., Chopp M. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol 2007, 62:49-58.
8. Chen J., Li Y., Wang L., Zhang Z., Lu D., Lu M., Chopp M. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001, 32:1005-1011.
9. Chen J., Zhang C., Jiang H., Li Y., Zhang L., Robin A., Katakowski M., Lu M., Chopp M. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 2005, 25:281-290.
10. Chen J., Zhang Z.G., Li Y., Wang L., Xu Y.X., Gautam S.C., Lu M., Zhu Z., Chopp M. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res 2003, 92:692-699.
11. Chen J., Zhang Z.G., Li Y., Wang Y., Wang L., Jiang H., Zhang C., Lu M., Katakowski M., Feldkamp C.S., Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003, 53:743-751.
12. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., Kostis J.B., Sheps D.S., Brinton E.A. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263-1270.
13. Fan H.G., Li L.T., Zhang X.J., Liu Y., Yang C.H., Yang Y., Yin J. Oxymatrine downregulates TLR4, TLR2, MyD88, and NF-kappaB and protects rat brains against focal ischemia. Mediators Inflamm 2009, 2009:704706.
14. Farmer D.G.S., Kennedy S. RAGE, vascular tone and vascular disease. Pharmacol Ther 2009, 124:185-194.
15. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., Suffredini A.F. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660.
16. Goldstein R.S., Gallowitsch-Puerta M., Yang L., Rosas-Ballina M., Huston J.M., Czura C.J., Lee D.C., Ward M.F., Bruchfeld A.N., Wang H., Lesser M.L., Church A.L., Litroff A.H., Sama A.E., Tracey K.J. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006, 25:571-574.
17. Han J., Zhong J., Wei W., Wang Y., Huang Y., Yang P., Purohit S., Dong Z., Wang M.H., She J.X., Gong F., Stern D.M., Wang C.Y. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008, 57:2118-2127.
18. Kim J.B., Lim C.M., Yu Y.M., Lee J.K. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 2008, 86:1125-1131.
19. Kim J.B., Sig Choi J., Yu Y.M., Nam K., Piao C.S., Kim S.W., Lee M.H., Han P.L., Park J.S., Lee J.K. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006, 26:6413-6421.
20. Kruger B., Krick S., Dhillon N., Lerner S.M., Ames S., Bromberg J.S., Lin M., Walsh L., Vella J., Fischereder M., Kramer B.K., Colvin R.B., Heeger P.S., Murphy B.T., Schroppel B. Donor toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A 2009, 106:3390-3395.
21. Lakhan S.E., Kirchgessner A., Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009, 7:97.
22. Li W., Prakash R., Kelly-Cobbs A.I., Ogbi S., Kozak A., El-Remessy A.B., Schreihofer D.A., Fagan S.C., Ergul A. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes 2010, 59:228-235.
23. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., Ferguson T.B., Ford E., Furie K., Gillespie C., Go A., Greenlund K., Haase N., Hailpern S., Ho P.M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M.M., Meigs J., Mozaffarian D., Mussolino M., Nichol G., Roger V.L., Rosamond W., Sacco R., Sorlie P., Thom T., Wasserthiel-Smoller S., Wong N.D., Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
24. Maillard-Lefebvre H., Boulanger E., Daroux M., Gaxatte C., Hudson B.I., Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology 2009, 48:1190-1196.
25. Mast H., Thompson J.L., Lee S.H., Mohr J.P., Sacco R.L. Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. Stroke 1995, 26:30-33.
26. Miller R.K., Qadota H., Stark T.J., Mercer K.B., Wortham T.S., Anyanful A., Benian G.M. CSN-5, a component of the COP9 signalosome complex, regulates the levels of UNC-96 and UNC-98, two components of M-lines in Caenorhabditis elegans muscle. Mol Biol Cell 2009, 20:3608-3616.
27. Muhammad S., Barakat W., Stoyanov S., Murikinati S., Yang H., Tracey K.J., Bendszus M., Rossetti G., Nawroth P.P., Bierhaus A., Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008, 28:12023-12031.
28. Nedergaard M., Gjedde A., Diemer N.H. Hyperglycaemia protects against neuronal injury around experimental brain infarcts. Neurol Res 1987, 9:241-244.
29. Oozawa S., Mori S., Kanke T., Takahashi H., Liu K.Y., Tomono Y., Asanuma M., Miyazaki I., Nishibori M., Sano S. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J 2008, 72:1178-1184.
30. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377.
31. Qiu J., Nishimura M., Wang Y., Sims J.R., Qiu S., Savitz S.I., Salomone S., Moskowitz M.A. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008, 28:927-938.
32. Qiu J.H., Xu J.A., Zheng Y., Wei Y., Zhu X.X., Lo E.H., Moskowitz M.A., Sims J.R. High-mobility group box 1 promotes metalloproteinase-9 upregulation through toll-like receptor 4 after cerebral ischemia. Stroke 2010, 41:2077-2082.
33. Rosenson R.S. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003, 171:87-96.
34. Shehadah A., Chen J., Zacharek A., Cui Y., Ion M., Roberts C., Kapke A., Chopp M. Niaspan treatment induces neuroprotection after stroke. Neurobiol Dis 2010, 40:277-283.
35. Tavintharan S., Woon K., Pek L.T., Jauhar N., Dong X., Lim S.C., Sum C.F. Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. Atherosclerosis 2011, 215:176-179.
36. Veloso CA, Fernandes JS, Volpe CM, Fagundes-Netto FS, Reis JS, Chaves MM, Nogueira-Machado JA (in press) TLR4 and RAGE: similar routes leading to inflammation in type 2 diabetic patients. Diabetes Metab, in press.
37. Williams M.D., Nadler J.L. Inflammatory mechanisms of diabetic complications. Curr Diab Rep 2007, 7:242-248.
38. Yamagishi S., Nakamura K., Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009, 60:174-178.
39. Yang H., Wang H., Czura C.J., Tracey K.J. The cytokine activity of HMGB1. J Leukoc Biol 2005, 78:1-8.
40. Yang Q.W., Wang J.Z., Li J.C., Zhou Y., Zhong Q., Lu F.L., Xiang J. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 2010, 30:243-254.
41. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., Fenton M.J., Tracey K.J., Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.
42. Zurolo E., Iyer A., Maroso M., Carbonell C., Anink J.J., Ravizza T., Fluiter K., Spliet W.G., van Rijen P.C., Vezzani A., Aronica E. Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain 2011, 134:1015-1032.